PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Phase 3

Completed

Conditions: Respiratory Tract Infection

Interventions: Biological: Placebo
Biological: RSVpreF

First Posted Date: 2020-06-09

Last Posted Date: 2024-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 14699

Registration Number: NCT04424316

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center Drug Information Center Dept, Los Angeles, California, United States
🇺🇸
Wayne State University Physician Group, Southfield, Michigan, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

and more 455 locations

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: PF-06650833
Drug: PF-06651600
Drug: Tofacitinib

First Posted Date: 2020-06-04

Last Posted Date: 2023-04-07

Lead Sponsor: Pfizer

Target Recruit Count: 460

Registration Number: NCT04413617

Locations: 🇧🇬
Independent Medical Diagnostic Laboratory Mediscan EOOD, Plovdiv, Bulgaria
🇧🇬
MHAT Plovdiv AD, Plovdiv, Bulgaria
🇧🇬
DCC Sveti Georgi EOOD, Plovdiv, Bulgaria

and more 140 locations

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Tofacitinib

First Posted Date: 2020-06-02

Last Posted Date: 2020-07-31

Lead Sponsor: Pfizer

Registration Number: NCT04412252

Locations: 🇺🇸
LSUHSC-Shreveport, Shreveport, Louisiana, United States
🇺🇸
Ochsner LSU Health Shreveport Academic Medical Center, Shreveport, Louisiana, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 3 locations

Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: TA-46
Other: Placebo

First Posted Date: 2020-06-01

Last Posted Date: 2020-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 78

Registration Number: NCT04410809

Locations: 🇳🇱
PRA, Groningen, Netherlands

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Phase 2

Completed

Conditions: Acute Migraine

Interventions: Drug: Zavegepant (BHV-3500)

First Posted Date: 2020-05-29

Last Posted Date: 2023-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 974

Registration Number: NCT04408794

Locations: 🇺🇸
Ki Health Partners, LLC dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸
Pharmacology Research Institute, Los Alamitos, California, United States

and more 58 locations

PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tofacitinib MR 11 mg
Drug: tofacitinib IR 5 mg

First Posted Date: 2020-05-27

Last Posted Date: 2020-05-27

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT04403776

Locations: 🇨🇳
Shuguang Hospital Affiliated to Shanghai University of TCM/Phase I Unit, Shanghai, China

Actigraphy Improvement With Voxelotor (ActIVe) Study

Phase 4

Completed

Conditions: Sickle Cell Disease
Sickle Cell Anemia

Interventions: Drug: Voxelotor

First Posted Date: 2020-05-22

Last Posted Date: 2023-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT04400487

Locations: 🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 7 locations

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Phase 2

Completed

Conditions: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease

Interventions: Drug: PF-06865571
Drug: Placebo
Drug: PF-05221304

First Posted Date: 2020-05-22

Last Posted Date: 2023-04-13

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT04399538

Locations: 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
Excel Medical Clinical Trials, Boca Raton, Florida, United States
🇺🇸
Optimus U Corporation, Miami, Florida, United States

and more 16 locations

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Enbrel

First Posted Date: 2020-05-21

Last Posted Date: 2021-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 486

Registration Number: NCT04398732

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

Terminated

Conditions: Breast Cancer

First Posted Date: 2020-05-20

Last Posted Date: 2023-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 975

Registration Number: NCT04396626

Locations: 🇺🇸
Pfizer United States, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy